Beta Bionics, Inc.
BBNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.99 | 0.16 | -0.03 | 0.19 |
| FCF Yield | -1.15% | -2.43% | -5.40% | -1.45% |
| EV / EBITDA | -61.82 | -37.21 | -18.88 | -56.95 |
| Quality | ||||
| ROIC | -5.56% | -6.37% | -5.77% | -10.03% |
| Gross Margin | 55.48% | 53.80% | 50.86% | 57.19% |
| Cash Conversion Ratio | 0.61 | 0.81 | 0.70 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 205.94% | 4,272,960.35% | 4,117,846.32% | 4,023,180.90% |
| Free Cash Flow Growth | 34.88% | 24.30% | -36.85% | -28.66% |
| Safety | ||||
| Net Debt / EBITDA | 2.28 | 1.75 | 1.97 | 1.32 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.60 | 0.62 | 0.55 | 0.66 |
| Cash Conversion Cycle | 165.09 | 160.66 | 183.65 | 160.48 |